摘要
慢性肾脏疾病和心房颤动常在中老年患者中同时存在。在慢性肾脏疾病患者心房颤动恢复窦性节律和控制心室率的治疗中,要充分考虑药物的代谢途径。在预防血栓栓塞治疗中,要充分考虑药物的效益-风险比,减少出血发生率。对慢性肾脏疾病患者应慎用华法林,并作严密的国际标准化比率监测。新型抗凝药物的临床研究中包含了一部分慢性肾脏疾病患者,应作进一步研究以明确这些药物对慢性肾脏疾病患者的疗效和安全性。
Chronic kidney disease and atrial fibrillation may often coexist in mid- and aged patients. In the rhythm control and rate control for atrial fibrillation in chronic kidney patients, the metabolism route of the drugs should be fully considered. In the prevention of thrombo-embolism, the efficacy-risk ratio of drugs should be fully considered in order to reduce bleeding events. Warfarin should be used cautiously, and close international normalized ratio monitoring is needed. The clinical trial of new anticoagulant drugs include some chronic kidney disease patients, further searches for the efficacy and safety of these drugs in chronic kidney disease patients are needed.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2015年第11期821-826,共6页
Chinese Journal of New Drugs and Clinical Remedies
关键词
肾功能不全
慢性
心房颤动
抗凝药
renal insufficiency, chronic
atrial fibrillation
anticoagulants
